<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6351454</article-id><article-id pub-id-type="doi">10.3389/fonc.2019.00010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xuefei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/623384/overview"/></contrib><contrib contrib-type="author"><name><surname>Jolly</surname><given-names>Mohit Kumar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><xref ref-type="author-notes" rid="fn003"><sup>&#x02021;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/189403/overview"/></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Jason T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/669969/overview"/></contrib><contrib contrib-type="author"><name><surname>Pienta</surname><given-names>Kenneth J.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/670024/overview"/></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Herbert</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/247540/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Center for Theoretical Biological Physics, Rice University</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Bioengineering, Rice University</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff><aff id="aff3"><sup>3</sup><institution>Medical Scientist Training Program, Baylor College of Medicine</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff><aff id="aff4"><sup>4</sup><institution>The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Physics and Astronomy, Rice University</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Physics, Northeastern University</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Ubaldo Emilio Martinez-Outschoorn, Thomas Jefferson University, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Rafael Coelho Lopes De Sa, University of Massachusetts Amherst, United States; Virendra K. Chaudhri, Cincinnati Children's Hospital Medical Center, United States</p></fn><corresp id="c001">*Correspondence: Herbert Levine <email>herbert.levine@rice.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology</p></fn><fn fn-type="other" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn><fn fn-type="present-address" id="fn003"><p>&#x02021;Present Address: Mohit Kumar Jolly, Centre for BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>9</volume><elocation-id>10</elocation-id><history><date date-type="received"><day>03</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>03</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Li, Jolly, George, Pienta and Levine.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Li, Jolly, George, Pienta and Levine</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Tumor microenvironments contain multiple cell types interacting among one another via different signaling pathways. Furthermore, both cancer cells and different immune cells can display phenotypic plasticity in response to these communicating signals, thereby leading to complex spatiotemporal patterns that can impact therapeutic response. Here, we investigate the crosstalk between cancer cells and macrophages in a tumor microenvironment through <italic>in silico</italic> (computational) co-culture models. In particular, we investigate how macrophages of different polarization (M<sub>1</sub> vs. M<sub>2</sub>) can interact with epithelial-mesenchymal plasticity of cancer cells, and conversely, how cancer cells exhibiting different phenotypes (epithelial vs. mesenchymal) can influence the polarization of macrophages. Based on interactions documented in the literature, an interaction network of cancer cells and macrophages is constructed. The steady states of the network are then analyzed. Various interactions were removed or added into the constructed-network to test the functions of those interactions. Also, parameters in the mathematical models were varied to explore their effects on the steady states of the network. In general, the interactions between cancer cells and macrophages can give rise to multiple stable steady-states for a given set of parameters and each steady state is stable against perturbations. Importantly, we show that the system can often reach one type of stable steady states where cancer cells go extinct. Our results may help inform efficient therapeutic strategies.</p></abstract><kwd-group><kwd>MET&#x02013;mesenchymal-to-epithelial transition</kwd><kwd>EMT&#x02013;epithelial-to-mesenchymal transition</kwd><kwd>M1-/M2-polarized macrophages</kwd><kwd>interaction network</kwd><kwd>multi-stability</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Stand Up To Cancer<named-content content-type="fundref-id">10.13039/100009730</named-content></funding-source></award-group><award-group><funding-source id="cn002">Cancer Prevention and Research Institute of Texas<named-content content-type="fundref-id">10.13039/100004917</named-content></funding-source></award-group><award-group><funding-source id="cn003">Foundation for the National Institutes of Health<named-content content-type="fundref-id">10.13039/100000009</named-content></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><equation-count count="4"/><ref-count count="63"/><page-count count="12"/><word-count count="8881"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Cancer has been largely considered as a cell-autonomous disease, but recent investigations have highlighted the crucial role of the tumor microenvironment in determining cancer progression (<xref rid="B1" ref-type="bibr">1</xref>). Cancer cells can communicate bi-directionally through various mechanical and/or chemical ways with their neighboring cancer cells (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>), and/or with other components of the tumor microenvironment such as macrophages and fibroblasts, driving aggressive malignancy (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>). The interconnected feedback loops formed by these interactions can often generate many emergent outcomes for the tumor. Interestingly, many of the latest therapeutic innovations such as immunotherapy are aimed at targeting aspects of the tumor microenvironment instead of the cancer cells (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Tumor-associated macrophages (TAMs) are one of the most abundant immune cell populations in the microenvironment (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). They have been shown to promote cancer progression in many ways, such as promoting angiogenesis, suppressing function of cytotoxic T lymphocytes, and assisting extravasation of cancer cells (<xref rid="B8" ref-type="bibr">8</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>). Generally, the secretome and functions of TAMs have been shown to be close to that of the so-called alternatively activated macrophages (M<sub>2</sub>) (<xref rid="B13" ref-type="bibr">13</xref>). In the case of pathogen infections, macrophages that can engulf the pathogen and present processed antigens to adaptive immune cells, are generally characterized as the classically activated ones (M<sub>1</sub>) (<xref rid="B14" ref-type="bibr">14</xref>). M<sub>1</sub> and M<sub>2</sub> macrophages have different roles during wound healing: while M<sub>1</sub> macrophages initiate inflammatory responses, M<sub>2</sub> macrophages contribute to tissue restoration (<xref rid="B13" ref-type="bibr">13</xref>). In the context of cancer, M<sub>1</sub> macrophages have been generally considered anti-tumor (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>), whereas M<sub>2</sub> macrophages have been considered as pro-tumor (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>However, macrophage polarization is not as rigid as the differentiation of T lymphocytes (<xref rid="B18" ref-type="bibr">18</xref>); instead, M<sub>1</sub>, M<sub>2</sub>, and any intermediate state(s) of macrophage polarization are quite plastic (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Thus, the idea that reverting TAMs in the cancer microenvironment to its cancer-suppressing counterpart is tempting, the proof of principle of which has been demonstrated in mice models (<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Not only TAMs, but also cancer cells themselves can be extremely plastic, a canonical example of which is epithelial-mesenchymal plasticity, i.e., cancer cells can undergo varying degrees of Epithelial-Mesenchymal Transition (EMT) and its reverse Mesenchymal-Epithelial Transition (MET) (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). EMT/MET has been associated with metastasis (<xref rid="B28" ref-type="bibr">28</xref>), chemoresistance (<xref rid="B29" ref-type="bibr">29</xref>), tumor-initiation potential (<xref rid="B30" ref-type="bibr">30</xref>), resistance against cell death (<xref rid="B31" ref-type="bibr">31</xref>), and evading the immune system (<xref rid="B32" ref-type="bibr">32</xref>).</p><p>Importantly, macrophages and cancer cells can interact with and influence the behavior of one another, as shown by many <italic>in vitro</italic> experiments. Specifically, some epithelial cancer cells are capable of polarizing monocytes into M<sub>1</sub>-like macrophages (<xref rid="B33" ref-type="bibr">33</xref>). Forming a negative feedback loop, these M<sub>1</sub>-like macrophages can decrease the confluency of the cancer cells that polarized them (<xref rid="B33" ref-type="bibr">33</xref>). Moreover, pre-polarized M<sub>1</sub> macrophages can induce senescence and apoptosis in human cancer cell lines A549 (<xref rid="B34" ref-type="bibr">34</xref>) and MCF-7 (<xref rid="B35" ref-type="bibr">35</xref>). Intriguingly, factors released by apoptosis of cancer cells can convert M<sub>1</sub> macrophages into M<sub>2</sub>-like macrophages (<xref rid="B35" ref-type="bibr">35</xref>), thus switching macrophage population from being tumor-suppressive to being tumor-promoting. On the other hand, mesenchymal cancer cells can polarize monocytes into M<sub>2</sub>-like macrophages (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>), that can in turn assist EMT (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Thus, the interaction network among macrophages and cancer cells is formidably complex, and the emergent dynamics of these interactions can be non-intuitive (<xref rid="B39" ref-type="bibr">39</xref>) yet are often crucial in deciding the success of therapeutic strategies targeting cancer and/or immune cells. For example, even if TAMs at some time can be converted exogenously to M<sub>1</sub>-like macrophages, if most cancer cells still tend to polarize monocytes to TAMs, other coordinated perturbations may be needed at different time-points to restrict the aggressiveness of the disease.</p><p>Here, we develop mathematical models to capture the abovementioned set of interactions among cancer cells in varying phenotypes (epithelial and mesenchymal) and macrophages of different polarizations (M<sub>1</sub>-like and M<sub>2</sub>-like). We characterize the multiple steady states of the network that can be obtained as a function of different initial conditions and key parameters, and thus analyze various potential compositions of cellular populations in the tumor microenvironment. This <italic>in silico</italic> co-culture system can not only help explain <italic>in vitro</italic> multiple experimental observations and clinical data, but also help acquire novel insights into designing effective therapeutic strategies aimed at cancer cells and/or macrophages.</p></sec><sec sec-type="results" id="s2"><title>Results</title><sec><title>Crosstalk Among Cancer Cells and Macrophages Can Lead to Two Distinct Categories of Steady States</title><p>We first considered the following interactions in setting up our mathematical model: (a) proliferation of epithelial and mesenchymal cells (but not that of monocytes M<sub>0</sub>, or macrophages M<sub>1</sub> and M<sub>2</sub>), (b) EMT promoted by M<sub>2</sub>-like macrophages and MET promoted by M<sub>1</sub>-like macrophages, (c) polarization of monocytes (M<sub>0</sub>) to M<sub>1</sub>-like cells aided by epithelial cells, and that to M<sub>2</sub>-like cells aided by mesenchymal cells, (d) induction of senescence in epithelial cells by M<sub>1</sub>-like macrophages (Figure <xref ref-type="fig" rid="F1">1A</xref>). No inter-conversion among M<sub>1</sub>-like and M<sub>2</sub>-like macrophages or cell-death of macrophages is considered here in this model (hereafter referred to as &#x0201c;Model I&#x0201d;; see section Methods).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Cancer-immune interplay can give rise to the co-existence of two types of steady states. <bold>(A)</bold> Interaction network for Model I. Conversions between cells are indicated by solid lines. Cell proliferation is indicated by dashed lines. Inhibition (in black) and activation (in red) is indicated by dotted lines. <bold>(B)</bold> Steady states of the epithelial population are plotted as a function of M<sub>2</sub>-like macrophage population. Stable steady states are plotted in solid blue lines and unstable steady states are plotted in dotted red line. The key parameters are as indicated. <bold>(C)</bold> As the cooperativity of epithelial cancer cells in their resistance of M<sub>2</sub>-promoted EMT is reduced, i.e., <italic>k</italic> = 4, 3, 2 (blue, cyan, and light-green line), the overlapped region between state I and II shrinks and then disappears. Increasing the cooperativity of M<sub>2</sub>-promoted EMT or M<sub>1</sub>-promoted MET, i.e., m and n increase from 1 to 2, can expand the overlapped region (between state I and II) of the system (dark-green lines). Stable steady states are plotted in solid lines and unstable steady states are plotted in dotted lines. <bold>(D)</bold> As the total number of macrophages (M<sub>c</sub>) increases, the overlapped region (between state I and II) of the system shrinks and then disappears.</p></caption><graphic xlink:href="fonc-09-00010-g0001"/></fig><p>Furthermore, this model also considers that mesenchymal cells can secrete soluble factors, such as TGF&#x003b2;, that can induce or maintain the mesenchymal state in autocrine or paracrine manners (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Therefore, we hypothesized that mesenchymal cells can resist M<sub>1</sub>-promoted MET. However, this resistance might not fully suppress MET, as MET still happens in the presence of M<sub>1</sub> macrophages (<xref rid="B38" ref-type="bibr">38</xref>). Therefore, in Equation (1), we assume a Hill-like function to represent the resistance to M<sub>1</sub>-promoted MET and the resistance term saturates to a finite value as a function of mesenchymal population M. And the corresponding half-saturation constant is <inline-formula><mml:math id="M1"><mml:msubsup><mml:mrow><mml:mtext>K</mml:mtext></mml:mrow><mml:mrow><mml:mtext>M</mml:mtext></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>. Similarly, epithelial cells adhere to each other via E-cadherin, sequestering &#x003b2;-catenin on the membrane, thus interfering with the induction of EMT (<xref rid="B42" ref-type="bibr">42</xref>). Thus, we hypothesized that the M<sub>2</sub>-promoted EMT can be inhibited by epithelial cells in a cooperative manner, because this inhibition of EMT requires direct physical cell-cell contact and hence involves multiple epithelial cells. Therefore, in Equation (1), we assume a Hill-like function to represent this resistance to M<sub>2</sub>-dependent EMT and the resistance term saturates to a finite value as a function of epithelial population E. And the corresponding half-saturation constant is <inline-formula><mml:math id="M2"><mml:msubsup><mml:mrow><mml:mtext>K</mml:mtext></mml:mrow><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>. Furthermore, the epithelial-cell-dependent term has a cooperativity parameter k to represent the effects of E-cadherin-&#x003b2;-catenin interaction between multiple epithelial cells.</p><p>Note that in all of our calculations, we assumed that there is a carrying-capacity of cells (N<sub>max</sub>, including both cancer cells and macrophages) in the co-culture system <italic>in vitro</italic>. We vary the initial number of different cells while keeping the total number of macrophages (M<sub>1</sub>+M<sub>2</sub>+M<sub>0</sub>) to be a constant (M<sub>c</sub>). Therefore, the maximum number of cancer cells will be N<sub>max</sub> -M<sub>c</sub>.</p><p>In Model I, the final populations of E, M, M<sub>1</sub>, and M<sub>2</sub> cells are simply determined by the following equations:</p><disp-formula id="E1"><mml:math id="M3"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><p>where &#x003b7;<sub>em</sub> and &#x003b7;<sub>me</sub> are the EMT and MET rate constants, respectively. The above equations give two categories of stable steady states: (a) state I, dominated by epithelial cancer cells, and (b) state II, dominated by mesenchymal cancer cells. The final steady state of the system depends on the number of M<sub>2</sub> macrophages in that state; since there are only three equations for four unknowns, M<sub>2</sub> can be used as a parameter specifying (possibly discrete set of) solutions. As soon as M<sub>2</sub>/N<sub>max</sub> crosses a threshold, the system switches from state I to state II (Figure <xref ref-type="fig" rid="F1">1B</xref>). This prediction is largely robust to parameter variation (Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref>).</p><p>Next, we explored what factors could change the qualitative behavior of the model, i.e., enable a smoother and continuous transition of epithelial and mesenchymal percentages as a function of the M<sub>2</sub>-macrophage population. We identified that reducing the cooperativity of epithelial cancer cells in their resistance of M<sub>2</sub>-promoted EMT can lead to a loss of the feature with two-types of steady states (Figure <xref ref-type="fig" rid="F1">1C</xref>, blue, cyan, and light-green lines). Conversely, increasing the cooperativity of M<sub>2</sub>-promoted EMT or M<sub>1</sub>-promoted MET can expand the region of overlapping between state I and II of the system (Figure <xref ref-type="fig" rid="F1">1C</xref>, green lines). Another factor that can alter the behavior of the model is the initial number of monocytes in the system. At high enough number of monocytes, the absolute number of cancer cells will be small, thus the effect of the cooperativity between epithelial cancer cells will be reduced, and consequently, as discussed above, the overlap of the two types of steady states of the system will disappear (Figure <xref ref-type="fig" rid="F1">1D</xref>). Together, this increased propensity of multi-stability in the system upon including cooperative effects in the interactions among different species (or variables) is reminiscent of observations in models of biochemical networks (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>Note that using the M<sub>2</sub>/N<sub>max</sub> as the &#x0201c;control variable&#x0201d; is specific for Model I, because there is no interconversion between M<sub>1</sub> and M<sub>2</sub> macrophages. For a given set of parameters, the steady state level of M<sub>2</sub> can vary continuously from 0 to M<sub>c</sub> (Figures <xref ref-type="fig" rid="F1">1B&#x02013;D</xref>), and in practice is determined by the initial conditions (initial number of E, M, M<sub>1</sub>, M<sub>2</sub>, and M<sub>0</sub>). For models in the following sections, M<sub>2</sub>/N<sub>max</sub> will be shown to be fixed to discrete allowed values (instead of continuously varying) for a given set of parameters. For example, if we add a very small conversion rate between M<sub>1</sub> and M<sub>2</sub>, the steady state of the system will collapse to only one steady state (Figure <xref ref-type="supplementary-material" rid="SM1">S2</xref>): on the shorter time scale, the trajectory of the system (on the phase plane of E and M<sub>2</sub>) will first converge to one steady state in Model I (with the same M<sub>2</sub>/N<sub>max</sub>); on the longer time scale, as determined by the value of inter-conversion rate between M<sub>1</sub> and M<sub>2</sub>, the system will slowly evolve to the steady state (blue dot in Figure <xref ref-type="supplementary-material" rid="SM1">S2</xref>), following along the now-approximate steady states in Model I.</p></sec><sec><title>Cancer-Cell Enhanced Interconversion Between M<sub>1</sub>- and M<sub>2</sub>-Like Macrophages Lead to Bi-Stability</title><p>In the next iteration of our model (hereafter referred to as &#x0201c;Model II&#x0201d;), we included the possibility of interconversion between M<sub>1</sub>-like and M<sub>2</sub>-like macrophages, as reported in the literature (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>) (Figure <xref ref-type="fig" rid="F2">2A</xref>, see section Methods). We first assume constant interconversion between M<sub>1</sub> and M<sub>2</sub> (with rates denoted as <inline-formula><mml:math id="M4"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M5"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>) and investigate the effects of varying the rate of conversion of mesenchymal cells to epithelial cells (&#x003b7;<sub>me</sub>). At small values of &#x003b7;<sub>me</sub>, the system has small number of epithelial cells, which is equivalent to state II in Model I; with increasing &#x003b7;<sub>me</sub>, a threshold is crossed, and the system can switch to states with larger number of epithelial cells, which is equivalent to state I in Model I (solid black lines, Figure <xref ref-type="fig" rid="F2">2B</xref>). Thus, we can observe bi-stability of cancer cell population in this system. However, the populations of macrophages stay constant as a function of &#x003b7;<sub>me</sub>, since the M<sub>1</sub>/M<sub>2</sub> ratio is simply determined by <inline-formula><mml:math id="M6"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>/<inline-formula><mml:math id="M7"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula> according to Equation (2) when &#x003b7;<sub>12</sub> = &#x003b7;<sub>21</sub> = 0). In this model, we focused on increased cooperativity of M<sub>2</sub>-assisted EMT and M<sub>1</sub>-assisted MET (i.e., m = n = 2), because the interconversion between M<sub>1</sub> and M<sub>2</sub>, in absence of such cooperativity (as considered in model I with m = n = 1; Figure <xref ref-type="fig" rid="F1">1B</xref>), gives rise to a narrower bi-stable region (Figure <xref ref-type="supplementary-material" rid="SM1">S3</xref>). Note again that in our calculations, we assumed that there is a carrying-capacity of cells (N<sub>max</sub>, including both cancer cells and macrophages) in the co-culture system <italic>in vitro</italic>. Again, the total number of macrophages is constant, since no cell death or cell division of macrophages is considered.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Effects of interconversion between M<sub>1</sub> and M<sub>2</sub> cells, mediated by cancer cells. <bold>(A)</bold> Network of Model II. <bold>(B,C)</bold> Steady states of the epithelial <bold>(B)</bold> or M<sub>1</sub>
<bold>(C)</bold> populations are plotted as a function of &#x003b7;<sub>me</sub>. Stable steady states are plotted in solid lines and unstable steady states are plotted in dotted lines. The key parameters in <bold>(B,C)</bold> are: &#x003b7;<sub>12</sub> = &#x003b7;<sub>21</sub> = 0 (for black lines) or 1/72 h<sup>&#x02212;1</sup> (for blue lines), <italic>m</italic> = 2, <italic>n</italic> = 2, <italic>k</italic> = 4, <inline-formula><mml:math id="M8"><mml:msubsup><mml:mrow><mml:mo>&#x003b7;</mml:mo></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula> = <inline-formula><mml:math id="M9"><mml:msubsup><mml:mrow><mml:mo>&#x003b7;</mml:mo></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo></mml:math></inline-formula>1/72 h<sup>&#x02212;1</sup>. <bold>(D)</bold> In this plot, the key parameters are: &#x003b7;<sub>21</sub> = 1/72 h<sup>&#x02212;1</sup> (for blue lines) or 1/36 h<sup>&#x02212;1</sup> (for green lines), <italic>m</italic> = 2, <italic>n</italic> = 2, <italic>k</italic> = 4, <inline-formula><mml:math id="M10"><mml:msubsup><mml:mrow><mml:mo>&#x003b7;</mml:mo></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula> = <inline-formula><mml:math id="M11"><mml:msubsup><mml:mrow><mml:mo>&#x003b7;</mml:mo></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula> = 1/72 h<sup>&#x02212;1</sup>, and &#x003b7;<sub>12</sub> = 1/72 h<sup>&#x02212;1</sup>. In <bold>(B,D)</bold>, the gray line is the maximum fraction of cancer cells (=0.7) as M<sub>c</sub> is set as 0.3.</p></caption><graphic xlink:href="fonc-09-00010-g0002"/></fig><p>We chose &#x003b7;<sub>me</sub> as a control parameter, because it can act as a bottleneck for the transition between the two types of stable steady states of the system. Lowering the transition threshold of &#x003b7;<sub>me</sub> can be helpful in a sense that the system can potentially stay at state I (high epithelial state, supposed to be less aggressive) only. Due to the inherent symmetry in the network, the effect of lowering the threshold of &#x003b7;<sub>me</sub> can be recapitulated via other perturbations, such as a smaller rate of M<sub>1</sub>-assisted MET (&#x003b7;<sub>em</sub>), lower M<sub>1</sub> to M<sub>2</sub> conversion rate (&#x003b7;<sub>12</sub>), or higher M<sub>2</sub> to M<sub>1</sub> conversion rate (&#x003b7;<sub>21</sub>) (Figure <xref ref-type="supplementary-material" rid="SM1">S4</xref>).</p><p>We next consider the case where interconversion between M<sub>1</sub>-like and M<sub>2</sub>-like macrophages is enhanced by cancer cells, i.e., mesenchymal cells enhance the M<sub>1</sub>-to-M<sub>2</sub> transition, while epithelial cells enhance M<sub>2</sub>-to-M<sub>1</sub> transition. In this case, we observe the existence of a bi-stable region, and the range of the epithelial-cell-low solution (equivalent to state II) is wider than that for the previous case without any effects of epithelial (E) and mesenchymal (M) cancer cells on M<sub>1</sub>-M<sub>2</sub> interconversion (Figures <xref ref-type="fig" rid="F2">2B,C</xref>, solid blue lines). The reason for the expanded epithelial-cell-low region is that the positive feedback loop between mesenchymal and M<sub>2</sub> cells makes the mesenchymal- and M<sub>2</sub>-dominated state more stable. Therefore, a higher &#x003b7;<sub>me</sub> is required to compensate for the effects of low M<sub>1</sub> population. For therapeutic purposes, state I is favored, for it is believed that epithelial cells are typically less aggressive than mesenchymal ones. Therefore, symmetrical mutual enhancement might not be helpful for the therapy because of the expanded epithelial-low (mesenchymal-high) region. For the same reason, the lower threshold of &#x003b7;<sub>me</sub> to switch from state II to state I also shift to a higher value, which means that for a small &#x003b7;<sub>me</sub>, the system will only have one stable steady state, i.e., state II with high number of mesenchymal cells.</p><p>In order to drive the system to be bi-stable at a smaller &#x003b7;<sub>me</sub>, we tested the case with asymmetrical interconversion rates between M<sub>1</sub> and M<sub>2</sub>, i.e., higher conversion rate from M<sub>2</sub> to M<sub>1</sub> enhanced by epithelial cells (&#x003b7;<sub>21</sub>). In this case, the lower threshold of &#x003b7;<sub>me</sub> can indeed shift to a smaller value (Figure <xref ref-type="fig" rid="F2">2D</xref>), which makes it theoretically possible to switch the system from state II (low epithelial cells) to state I (high epithelial cells) at a fairly small &#x003b7;<sub>me</sub> value.</p><p>In summary, our results for Model II suggest that one can switch the system from state II (low epithelial cells) to state I (high epithelial cells) by increasing both &#x003b7;<sub>me</sub> and the effective conversion from M<sub>2</sub> to M<sub>1</sub>. Note that the interactions in Model 2 are rather symmetric: the interconversion rates between M<sub>1</sub> and M<sub>2</sub> are either constants or enhanced by the corresponding cancer-cells. In the following section, we will consider the asymmetric case where only the M<sub>1</sub> to M<sub>2</sub> conversion is enhanced by factors released by apoptotic epithelial cancer cells.</p></sec><sec><title>Cell Apoptosis-Induced M1-to-M2 Conversion Leads to Symmetry Breaking in the Cancer-Immune Interaction Network</title><p>Finally, we incorporated one other set of experimentally documented interactions, i.e., M<sub>1</sub> macrophages can drive the apoptosis of epithelial cells, and factors released during cancer cell apoptosis can drive M<sub>1</sub>-to-M<sub>2</sub> conversion (referred as Model III, see section Methods) (<xref rid="B35" ref-type="bibr">35</xref>). The newly introduced interactions are highlighted in thick lines in Figure <xref ref-type="fig" rid="F3">3A</xref>. This interaction induces &#x0201c;symmetry breaking&#x0201d; (<xref rid="B46" ref-type="bibr">46</xref>) in the system, as previously most of the interactions considered were of a &#x0201c;symmetric&#x0201d; nature, i.e., M<sub>1</sub> cells driving MET and M<sub>2</sub> cells driving EMT, and epithelial cells driving M<sub>1</sub> maturation while mesenchymal cells driving M<sub>2</sub> maturation. With this new interaction, the system is now biased against epithelial cells, because (a) epithelial but not mesenchymal cells, are killed by M<sub>1</sub>-macrophages, and (b) their dead counterparts may convert M<sub>1</sub> to M<sub>2</sub> cells that can, in turn, convert some epithelial cells to mesenchymal ones (EMT). In addition, the conversion from M<sub>2</sub> to M<sub>1</sub> is essential to bring the system back from the mesenchymal-cancer-cell biased state and it can be enhanced by introducing IL-12 (<xref rid="B45" ref-type="bibr">45</xref>) or Type 1 T helper cells (<xref rid="B44" ref-type="bibr">44</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Steady state solutions for a model including the M<sub>1</sub> to M<sub>2</sub> conversion assisted by apoptotic epithelial cancer cells<bold>. (A)</bold> Network of Model III. In this network, M<sub>1</sub> induces the apoptosis of epithelial cancer cells. And the factors released by apoptotic cancer cells enhance the M<sub>1</sub> to M<sub>2</sub> conversion. These interactions are highlighted by thicker lines. <bold>(B&#x02013;E)</bold> Steady states of the epithelial <bold>(B)</bold>, mesenchymal <bold>(C,D)</bold> and M<sub>1</sub>
<bold>(E)</bold> populations are plotted as a function of &#x003b7;<sub>me</sub>. <bold>(D)</bold> is a zoomed-in version of <bold>(C)</bold>. Stable steady states are plotted in solid lines and unstable steady states are plotted in dotted lines. The model-specific parameters are: &#x003b2; = 1/36 h<sup>&#x02212;1</sup>, &#x003b2;<sub>c</sub> = 1/1200 h<sup>&#x02212;1</sup>, &#x003b7;<sub>12</sub> = &#x003b7;<sub>21</sub> = 1/72 h<sup>&#x02212;1</sup>. When &#x003b7;<sub>me</sub> is higher than a critical value <inline-formula><mml:math id="M12"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>a</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>, the steady state E = M = 0 becomes stable <bold>(D)</bold>. When &#x003b7;<sub>me</sub> is higher than a critical value <inline-formula><mml:math id="M13"><mml:msubsup><mml:mrow><mml:mo>&#x003b7;</mml:mo></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>, the steady state E = M = 0 is the only stable steady state of the system. <bold>(F)</bold> For a given &#x003bb;<sub>M</sub>, the critical value <inline-formula><mml:math id="M14"><mml:msubsup><mml:mrow><mml:mo>&#x003b7;</mml:mo></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> is plotted.</p></caption><graphic xlink:href="fonc-09-00010-g0003"/></fig><p>Thus, in the parameter region investigated, there are 3 types of stable steady states, which are represented by solid blue, red and black lines, respectively. At small values of the control parameter &#x003b7;<sub>me</sub> (rate of M<sub>1</sub> macrophage assisted MET), there is only one type of stable steady state: the system is biased toward the mesenchymal-dominated state (solid blue curves in Figures <xref ref-type="fig" rid="F3">3B&#x02013;E</xref>), whereas the cancer-extinction state (E = M = 0, dashed black curves in Figures <xref ref-type="fig" rid="F3">3B&#x02013;E</xref>) is unstable. As &#x003b7;<sub>me</sub> increases and goes across a critical value <inline-formula><mml:math id="M15"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>a</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo></mml:math></inline-formula>0.0626 h<sup>&#x02212;1</sup>), the extinction state (E = M = 0) becomes stable as well as a new set of steady states emerges (red lines in Figures <xref ref-type="fig" rid="F3">3B&#x02013;E</xref>). Between &#x003b7;<sub>me</sub> = 0.0663 h<sup>&#x02212;1</sup> and &#x003b7;<sub>me</sub> = 0.0747 h<sup>&#x02212;1</sup>, the steady states depicted as a solid red line (Figures <xref ref-type="fig" rid="F3">3B&#x02013;E</xref>) are stable; here both populations of epithelial and mesenchymal cancer cells are at a low level. This phenomenon can be understood in the following sense: at higher &#x003b7;<sub>me</sub>, proliferating mesenchymal cells are continuously being converted to epithelial cells, which will be killed by M<sub>1</sub> macrophages. This effect brings down the overall fraction of cancer cells. Note that in this region, three types of stable steady states co-exist in the system for a given set of parameters. As &#x003b7;<sub>me</sub> increases and goes across <inline-formula><mml:math id="M16"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>b</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo></mml:math></inline-formula>0.0747 h<sup>&#x02212;1</sup>, the stable steady states in solid red lines disappears and the other two types of stable steady states co-existed (solid blue and black lines in Figures <xref ref-type="fig" rid="F3">3B&#x02013;E</xref>). As &#x003b7;<sub>me</sub> further increases and goes across <inline-formula><mml:math id="M17"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo></mml:math></inline-formula>0.1532 h<sup>&#x02212;1</sup>, there is only one stable steady state: cancer cells are necessarily eliminated from the system. We note in passing that the instability that drives the red solution unstable as &#x003b7;<sub>me</sub> is lowered past 0.0663 h<sup>&#x02212;1</sup> is a Hopf bifurcation to an unstable limit cycle.</p><p>Furthermore, for the breast cancer cell line MDA-MB-231 used in Yang et al. (<xref rid="B38" ref-type="bibr">38</xref>), &#x003b7;<sub>me</sub> is estimated to be around 1/120 h<sup>&#x02212;1</sup> (~0.0083 h<sup>&#x02212;1</sup>). In order to explore the conditions for the absolute extinction of cancer cells around the estimated &#x003b7;<sub>me</sub>, we varied different parameters (such as &#x003bb;<sub>M</sub>, &#x003b7;<sub>em</sub>, and &#x003b7;<sub>21</sub>) to get the corresponding <inline-formula><mml:math id="M18"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> where the extinction state is the only stable steady state of the system. We found that lowering the growth rate of mesenchymal cells (&#x003bb;<sub>M</sub>) can reduce <inline-formula><mml:math id="M19"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> to the nominal experimental value 1/120 h<sup>&#x02212;1</sup> (Figure <xref ref-type="fig" rid="F3">3F</xref>) whereas lowering down &#x003b7;<sub>em</sub> or increasing &#x003b7;<sub>21</sub> might not (Figure <xref ref-type="supplementary-material" rid="SM1">S5</xref>). Therefore, for therapeutic purposes, increasing &#x003b7;<sub>me</sub> and decreasing &#x003bb;<sub>M</sub> can be a promising combination to help to eliminate cancer cell populations. In addition, increasing the number of macrophages in the co-culture system can also shift <inline-formula><mml:math id="M20"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mtext>me</mml:mtext></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> to a lower value (Figure <xref ref-type="supplementary-material" rid="SM1">S6</xref>) because of a potentially higher level of cancer-killing M<sub>1</sub>-like macrophages.</p></sec><sec><title>EMT Scores Correlate With Multiple Genes Upregulated in M2 Macrophages</title><p>As a proof of principle for the predictions of our model, we investigated multiple TCGA datasets (see section Methods for the source of datasets), using our previously developed EMT scoring metric (<xref rid="B47" ref-type="bibr">47</xref>). This metric quantifies the extent of EMT in a particular sample, and correspondingly assigns a score between 0 (fully epithelial) and 2 (fully mesenchymal). We calculated the correlation coefficients for EMT scores with various genes reported to be differently regulated in M<sub>1</sub> or M<sub>2</sub> macrophages relative to M<sub>0</sub> macrophages. The list of those genes is taken from Jablonski et al. (<xref rid="B48" ref-type="bibr">48</xref>). Out of 52 genes investigated, we observed that many genes upregulated in M2 and downregulated in M<sub>1</sub> macrophages&#x02013;ACTN1, FLRT2, MRC1, PTGS1, RHOJ, TMEM158&#x02013;correlated positively with the EMT scores (Table <xref rid="T1" ref-type="table">1</xref>, first 6 rows) across multiple cancer types. The higher the EMT scores, the higher the levels of those genes, including the canonical M<sub>2</sub> macrophage marker CD206 (MRC1). On the other hand, out of the 52 genes investigated, many genes upregulated in M<sub>1</sub> macrophages but downregulated in M<sub>2</sub> macrophages&#x02013;FIIR, STAT1, RSAD2, TUBA4A, and XAF1&#x02013;showed either a negative or an overall weak positive correlation with EMT scores (Table <xref rid="T1" ref-type="table">1</xref>, last 5 rows). The only exception observed in this trend was that for ARHGP24 which correlated positively with EMT scores across cancer types. Together, these correlation results in multiple TCGA datasets offer a promising initial validation of our model predictions that a state dominated by epithelial cells typically has higher number of M<sub>1</sub> macrophages, while the other state dominated by mesenchymal cells typically has higher number of M<sub>2</sub> macrophages.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Correlation coefficients of expression levels of specific genes with EMT scores, across many TCGA datasets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>FC (M<sub><bold>1</bold></sub>/M<sub><bold>0</bold></sub>)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>FC (M<sub><bold>2</bold></sub>/M<sub><bold>0</bold></sub>)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Correlation Colorectal</bold><break/><bold> (<italic>n</italic> = 286)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Correlation Lung (<italic>n</italic> = 515)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Correlation Prostate (<italic>n</italic> = 497)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Correlation Breast (<italic>n</italic> = 1097)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" style="color:#ee1f25" rowspan="1" colspan="1">ACTN1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.46</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.37</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.32</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.41</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.32</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.13</td></tr><tr><td valign="top" align="left" style="color:#ee1f25" rowspan="1" colspan="1">FLRT2</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.47</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.29</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.33</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.36</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.33</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.40</td></tr><tr><td valign="top" align="left" style="color:#ee1f25" rowspan="1" colspan="1">MRC1 (CD206)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.02</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.82</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.31</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.28</td></tr><tr><td valign="top" align="left" style="color:#ee1f25" rowspan="1" colspan="1">PTGS1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.44</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">11.02</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.28</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.47</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.28</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.18</td></tr><tr><td valign="top" align="left" style="color:#ee1f25" rowspan="1" colspan="1">RHOJ</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.96</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.36</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.30</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.36</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.35</td></tr><tr><td valign="top" align="left" style="color:#ee1f25" rowspan="1" colspan="1">TMEM158</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.37</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.99</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.24</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.31</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.24</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">0.14</td></tr><tr><td valign="top" align="left" style="color:#3952a4" rowspan="1" colspan="1">ARHGAP24</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.38</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.36</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.29</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.24</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.29</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.37</td></tr><tr><td valign="top" align="left" style="color:#3952a4" rowspan="1" colspan="1">FIIR</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">3.43</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.41</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.12</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.44</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.12</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.19</td></tr><tr><td valign="top" align="left" style="color:#3952a4" rowspan="1" colspan="1">STAT1</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.27</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.27</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.02</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.29</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.02</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" style="color:#3952a4" rowspan="1" colspan="1">RSAD2</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">3.03</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.09</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.08</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.27</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.08</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.02</td></tr><tr><td valign="top" align="left" style="color:#3952a4" rowspan="1" colspan="1">TUBA4A</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.18</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.33</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.11</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.12</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.11</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">-0.01</td></tr><tr><td valign="top" align="left" style="color:#3952a4" rowspan="1" colspan="1">XAF1</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.09</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.25</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.05</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.27</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.05</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">0.05</td></tr></tbody></table><table-wrap-foot><p><italic>FC is the fold-change of gene expression levels in M<sub>1</sub> or M<sub>2</sub> macrophages relative to M<sub>0</sub>, which is measured in Jablonski et al. (<xref rid="B48" ref-type="bibr">48</xref>) for murine bone marrow derived macrophages polarized in vitro. Those shown in red indicated upregulated in M<sub>2</sub>, those in blue indicate upregulated in M<sub>1</sub>. In all cases, the Pearson's correlation coefficient (r) is calculated and the corresponding p-values of those correlation coefficients are &#x0003c; 0.05</italic>.</p></table-wrap-foot></table-wrap><p>Furthermore, to go beyond the correlation analysis between a single gene and the EMT-score, we investigated whether genes that are expressed higher in M<sub>2</sub>-like macrophages will be enriched in EMT-score-high tumors and whether genes that are expressed higher in M<sub>1</sub>-like macrophages will be enriched in EMT-score-low tumors. Again, the lists of genes that are expressed higher in M<sub>1</sub>- or M<sub>2</sub>-like macrophages are from Jablonski et al. (<xref rid="B48" ref-type="bibr">48</xref>) and the EMT-scores were calculated for each sample of the four TCGA dataset investigated in this work. We define a tumor to be EMT-score-high if its EMT-score is higher than the median score of the specific dataset and vice versa. Then, the expressions of a gene in EMT-score-high and low tumors in each dataset are used to determine whether this gene has a significantly high/low expression in EMT-score-high/low tumors. As expected, the genes that are expressed higher in M<sub>2</sub>-like macrophages (but lower in M<sub>1</sub>-like macrophages) are enriched in EMT-score-high tumors across the 4 types of cancers investigated (Table <xref rid="T2" ref-type="table">2</xref>). This result is consistent with our model predictions: M<sub>2</sub>-like macrophages and mesenchymal cancer cells tend to stably co-exist. However, somewhat to our surprise, the genes that expressed higher in M<sub>1</sub>-like macrophages (but lower in M<sub>2</sub>-like macrophages) are also enriched in EMT-score high tumors across the 4 types of cancers investigated (Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>). This result is not in line with our model prediction where M<sub>1</sub>-like macrophages are expected to stably co-exist with epithelial cancer cells. Possible reasons for this inconsistency will be discussed later. Nevertheless, the gene enrichment analysis in multiple TCGA datasets offer a promising initial validation of (most of) our model predictions.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>M<sub>2</sub>-associated gene set enrichment: Reported are all genes (out of 31 total) having statistically significant differential expression (samples segregated based on median EMT score) across TCGA colorectal adenocarcinoma (Adeno COL; <italic>n</italic> = 286), prostate adenocarcinoma (Adeno PCA; <italic>n</italic> = 497), invasive breast cancer (BCA invasive; <italic>n</italic> = 1097), and lung adenocarcinoma (Lung Adeno; <italic>n</italic> = 515).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Adeno COL</bold></th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Adeno PCA</bold></th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>BCA Invasive</bold></th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Lung Adeno</bold></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>M<sub><bold>2</bold></sub> Gene</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>p</italic>-value</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>95% CI</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>p</italic>-value</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>95% CI</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>p</italic>-value</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>95% CI</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>p</italic>-value</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>95% CI</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTN1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.36E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.14 0.39)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.61E&#x02212;17</td><td valign="top" align="center" rowspan="1" colspan="1">(0.41 0.65)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.52E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.11 0.28)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.65E&#x02212;13</td><td valign="top" align="center" rowspan="1" colspan="1">(0.36 0.61)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AMZ1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.75E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.23 0.55)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.03 0.14)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.50E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(0.03 0.28)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.92E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.35 0.87)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP6V0A1</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.03 0.16)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.89E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.16 &#x02212;0.01)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">4.22E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.16 &#x02212;0.03)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.20E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.07 0.28)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BCAR3</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.17 0.13)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.83E&#x02212;07</td><td valign="top" align="center" rowspan="1" colspan="1">(0.19 0.43)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.37E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(0.03 0.28)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.95E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.10 0.44)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCL22</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.07 0.56)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.13E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.13 0.53)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.21E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.22 0.56)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">5.58E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.36 0.90)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD300LD</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.03 0.08)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(0.00 0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.01 0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.02 0.03)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD83</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.08E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.33 0.67)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.94E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.15 0.40)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.86E&#x02212;14</td><td valign="top" align="center" rowspan="1" colspan="1">(0.33 0.55)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">5.03E&#x02212;12</td><td valign="top" align="center" rowspan="1" colspan="1">(0.43 0.76)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CDH1</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.15 0.10)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.10E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.34 &#x02212;0.08)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">1.13E&#x02212;28</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;1.25 &#x02212;0.88)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.59E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.33 &#x02212;0.02)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CHST7</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.71E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.13 0.49)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.06 0.13)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">8.64E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.15 0.32)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.44E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.20 0.46)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CLEC10A</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.55E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.19 0.89)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.33E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.22 0.64)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.52E&#x02212;15</td><td valign="top" align="center" rowspan="1" colspan="1">(0.63 1.05)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.21E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.52 1.06)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CLEC7A</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.35E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.38 0.98)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">9.67E&#x02212;07</td><td valign="top" align="center" rowspan="1" colspan="1">(0.24 0.56)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">6.03E&#x02212;10</td><td valign="top" align="center" rowspan="1" colspan="1">(0.32 0.62)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.63E&#x02212;16</td><td valign="top" align="center" rowspan="1" colspan="1">(0.67 1.07)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EGR2</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.21E&#x02212;13</td><td valign="top" align="center" rowspan="1" colspan="1">(0.88 1.47)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.16E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.24 0.77)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">5.27E&#x02212;27</td><td valign="top" align="center" rowspan="1" colspan="1">(0.71 1.02)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.60E&#x02212;11</td><td valign="top" align="center" rowspan="1" colspan="1">(0.48 0.87)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EMP2</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">1.38E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.39 &#x02212;0.09)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.97E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.09 0.30)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">9.75E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.25 &#x02212;0.03)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.23 0.11)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FLRT2</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.63E&#x02212;10</td><td valign="top" align="center" rowspan="1" colspan="1">(0.78 1.44)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.25E&#x02212;23</td><td valign="top" align="center" rowspan="1" colspan="1">(0.86 1.25)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.14E&#x02212;42</td><td valign="top" align="center" rowspan="1" colspan="1">(0.95 1.25)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">5.17E&#x02212;09</td><td valign="top" align="center" rowspan="1" colspan="1">(0.48 0.95)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IL6ST</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.97E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.12 0.60)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.50E&#x02212;07</td><td valign="top" align="center" rowspan="1" colspan="1">(0.52 1.16)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.69E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.24 0.76)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.09E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.40 0.83)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LMNA</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">2.50E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.27 &#x02212;0.02)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.51E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(0.01 0.26)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">1.29E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.22 &#x02212;0.03)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">1.73E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.38 &#x02212;0.14)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MATK</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.53E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.37 0.99)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.33 0.22)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">8.10E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.06 0.43)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">5.33E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.24 0.69)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MMP12</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.34 0.53)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.29 0.17)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.01 0.52)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.22E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.53 1.39)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MMP9</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.75E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.39 1.23)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.31 0.27)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.11 0.36)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">9.30E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.50 1.07)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MRC1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">8.03E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.71 1.51)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.75E&#x02212;08</td><td valign="top" align="center" rowspan="1" colspan="1">(0.35 0.73)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">6.62E&#x02212;19</td><td valign="top" align="center" rowspan="1" colspan="1">(0.66 1.03)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.54E&#x02212;10</td><td valign="top" align="center" rowspan="1" colspan="1">(0.67 1.20)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYC</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.50E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(0.02 0.41)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.15 0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.04 0.26)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.16 0.23)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OLFM1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.64E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.44 1.06)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.57E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.06 0.37)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.03 0.38)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.80E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.31 0.91)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P2RY1</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.47 0.06)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.34 0.19</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.96E&#x02212;16)</td><td valign="top" align="center" rowspan="1" colspan="1">(0.35 0.56)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.57E&#x02212;12</td><td valign="top" align="center" rowspan="1" colspan="1">(0.53 0.92)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PLK2</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.06 0.43)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.18E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.15 0.47)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.03 0.22)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.02 0.33)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PTGS1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">6.95E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.11 0.68)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">8.55E&#x02212;11</td><td valign="top" align="center" rowspan="1" colspan="1">(0.50 0.93)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.72E&#x02212;12</td><td valign="top" align="center" rowspan="1" colspan="1">(0.29 0.52)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.61E&#x02212;17</td><td valign="top" align="center" rowspan="1" colspan="1">(0.61 0.97)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RHOJ</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.08E&#x02212;09</td><td valign="top" align="center" rowspan="1" colspan="1">(0.51 0.99)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.83E&#x02212;20</td><td valign="top" align="center" rowspan="1" colspan="1">(0.53 0.80)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">7.62E&#x02212;32</td><td valign="top" align="center" rowspan="1" colspan="1">(0.55 0.77)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.23E&#x02212;09</td><td valign="top" align="center" rowspan="1" colspan="1">(0.31 0.61)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SOCS6</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">1.24E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.36 &#x02212;0.09)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.95E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.07 0.25)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.07E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.06 0.23)</td><td valign="top" align="center" style="color:#3952a4" rowspan="1" colspan="1">1.43E&#x02212;02</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.22 &#x02212;0.02)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TANC2</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.08 0.53)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.13 0.10)</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.05 0.23)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">9.54E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.05 0.35)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIAM1</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.22E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.31 0.93)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.06E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.22 0.53)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">6.42E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.13 0.39)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">6.75E&#x02212;24</td><td valign="top" align="center" rowspan="1" colspan="1">(0.83 1.21)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TMEM158</td><td valign="top" align="center" rowspan="1" colspan="1">ns</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x02212;0.11 0.40)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.49E&#x02212;07</td><td valign="top" align="center" rowspan="1" colspan="1">(0.32 0.72)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">1.68E&#x02212;03</td><td valign="top" align="center" rowspan="1" colspan="1">(0.12 0.51)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">3.35E&#x02212;05</td><td valign="top" align="center" rowspan="1" colspan="1">(0.30 0.83)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VWF</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.88E&#x02212;06</td><td valign="top" align="center" rowspan="1" colspan="1">(0.38 0.94)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.78E&#x02212;04</td><td valign="top" align="center" rowspan="1" colspan="1">(0.13 0.42)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">2.00E&#x02212;17</td><td valign="top" align="center" rowspan="1" colspan="1">(0.39 0.62)</td><td valign="top" align="center" style="color:#ee1f25" rowspan="1" colspan="1">4.89E&#x02212;07</td><td valign="top" align="center" rowspan="1" colspan="1">(0.33 0.74)</td></tr></tbody></table><table-wrap-foot><p><italic>For each gene, an unpaired t-test at significance level &#x003b1; = 0.05 was performed under the null hypothesis that EMT-high and EMT-low mean gene expression signatures are equal. Red p-values correspond to the M<sub>2</sub>-associated genes that are enriched in EMT-score-high tumors, whereas blue p-values correspond to the M<sub>2</sub>-associated genes that are enriched in EMT-score-low tumors. &#x0201c;ns&#x0201d; stands for non-significant</italic>.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>The tumor microenvironment involves multiple cell types that interact among each other in diverse ways, thus giving rise to a complex adaptive ecological system (<xref rid="B49" ref-type="bibr">49</xref>&#x02013;<xref rid="B51" ref-type="bibr">51</xref>). For such a system, mathematical models can help reveal the mechanisms underlying the emergent behavior and eventually aid in designing effective therapeutic strategies to modulate those aspects of the microenvironment that fuel disease aggressiveness (<xref rid="B52" ref-type="bibr">52</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>).</p><p>Here, we focused on the interactions among macrophages of different polarizations (M<sub>1</sub> and M<sub>2</sub>) and cancer cells with different phenotypes (epithelial and mesenchymal). Based on the literature, we focused on two types of models: with (Model II and III) or without (Model I) interconversion between M<sub>1</sub> and M<sub>2</sub> macrophages. All three models share a common feature: with a given set of parameters, multiple types of stable steady states can co-exist. More specifically, in Model I (without M<sub>1</sub>-M<sub>2</sub> interconversion), with a given set of parameters, the system can converge to continuous range of states depending on the initial condition. However, these steady states belong to two categories: state I with a higher epithelial population and state II with a lower epithelial population. After the system reaches a steady state, perturbations applied only to cancer cell populations cannot drive the system out of the original steady state whereas perturbations on macrophage populations will drive the system out of the original steady state. However, the perturbation on macrophage populations might not drive the system out of the original category of steady states unless the perturbation is sufficiently strong. In Model II and III, with a given set of parameters, the system can again converge to two types of steady states depending on the initial condition: state I with a higher epithelial population and state II with a lower (or even zero for Model III) epithelial population. Now, however, the states are discrete. After the system reaches a steady state, perturbations of any single cell population might not drive the system out of the original steady state. Therefore, in general, it is not easy to switch the cancer-macrophage system from a mesenchymal- and M<sub>2</sub>-dominated state to an epithelial- and M<sub>1</sub>-dominated state.</p><p>Mathematical approaches similar to ours may be useful in explaining, and even predicting, the efficacy of different therapeutic intervention(s) and their combinations. For example, various efforts have been made to switch populations of macrophages from M<sub>2</sub>- into M<sub>1</sub>-like (<xref rid="B25" ref-type="bibr">25</xref>), such as depletion of TAMs, reprogramming of TAMs toward M<sub>1</sub>-Like macrophages, inhibition of circulating monocyte recruitment into tumor, etc. The polarization of M<sub>2</sub> macrophages can also be altered via inhibiting the endothelial-mesenchymal transition (EndMT), a process similar to EMT (<xref rid="B59" ref-type="bibr">59</xref>). However, it is unclear that how effective these types of strategies would be. Our modeling studies suggest that when we consider the interactions in Model III, the efforts on manipulating the M<sub>1</sub>-M<sub>2</sub> interconversion might not be effective to eliminate cancer cells; whereas in Model II increasing the M<sub>2</sub>-to-M<sub>1</sub> conversion rate can help the system to switch to the epithelial cancer cell and M<sub>1</sub> macrophage dominated state, which is believed to be less aggressive. Therefore, the effective therapeutic strategies strongly depend on the type of interactions present between cancer cells and macrophages.</p><p>Furthermore, we attempted to investigate whether the model-predicted stable co-existence of M<sub>1</sub>-like macrophages and epithelial cancer cells (and likewise M<sub>2</sub>-like macrophages and mesenchymal cancer cells) can be seen in the TCGA dataset. Indeed, we can observe the enrichment of many genes that are expressed higher in M<sub>2</sub>-like macrophages in more mesenchymal tumors. This observation is consistent with our mathematical modeling analysis. However, we also detected the enrichment of genes that are expressed higher in M<sub>1</sub>-like macrophages in more mesenchymal tumors. There can be several reasons for the enrichment of M<sub>1</sub> genes in mesenchymal tumors: (i) the list of genes used here to identify the ones preferentially expressed in M<sub>1</sub>-like macrophages is from a study of mouse macrophages (<xref rid="B48" ref-type="bibr">48</xref>). For human macrophages, not as many markers have been validated as those in mice; future experiments can help characterize these better; (ii) for the TCGA sample used, the gene expression data that are used to calculate the EMT-score could be not exclusively that of cancer cells but may incorporate other types of cells, such as fibroblasts. Future experiments that can separate and measure gene expression of cancer cells separately, through techniques such as laser microdissection, will be more precise in quantifying the EMT status of cancer cells.</p><p>In addition, it is also important to recognize that our model suffers from limitations. For instance: (a) it does not consider spatial aspects of these interactions, for instance, mesenchymal cells may migrate and invade through the matrix, thus changing the interactions among the cells considered in our framework; (b) it does not consider the effects of senescence on epithelial cell growth (<xref rid="B60" ref-type="bibr">60</xref>); and (c) it considers EMT and macrophages polarization as a binary process, whereas emerging reports support the notion that in both cases there is likely to exist a spectrum of states/ phenotypes (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>). A more realistic model that can overcome the abovementioned assumptions and thus reflect the dynamics of tumor microenvironment more accurately can be used to help designing a more effective way to switch and stably maintain the system into a less aggressive state.</p><p>Despite the abovementioned limitations, our model can contribute to identifying key parameters of the system. For example, it suggests that to design an effective therapy to maintain the system in a M<sub>1</sub>-dominated and cancer-free steady state, not only the conversion rate from mesenchymal to epithelial cells should be significant, but also the growth rate of mesenchymal cells should be low enough. In other words, MET-inducing and cell-growth-suppressing mechanisms can together synergistically restrict disease aggressiveness.</p><p>In summary, our results show that the interaction network between tumor cells and macrophages may lead to multi-stability in the network: one state dominated by epithelial and M<sub>1</sub>-like cells, the other dominated by mesenchymal and M<sub>2</sub>-like cells. We also identify that inducing MET and inhibiting cancer-cell growth might be much more efficient in &#x0201c;normalizing&#x0201d; (<xref rid="B1" ref-type="bibr">1</xref>) the tumor microenvironment that can otherwise be engineered by cancer cells to support their growth (<xref rid="B63" ref-type="bibr">63</xref>).</p></sec><sec sec-type="methods" id="s4"><title>Methods</title><sec><title>Computational Models</title><p>According to <italic>in vitro</italic> experiments in literature, we construct three mathematical models. In Model I, factors secreted by epithelial (mesenchymal) cancer cells will polarize monocytes into M<sub>1</sub>-like (M<sub>2</sub>-like) macrophages. M<sub>1</sub>-like macrophages will induce senescence of epithelial cancer cells and convert mesenchymal cancer cells to epithelial ones. On the other hand, M<sub>2</sub>-like macrophages will convert epithelial cancer cells to mesenchymal ones. In addition, a mesenchymal cancer cell can secrete soluble factors to help maintain the mesenchymal state of itself and its neighbors, whereas an epithelial cancer cell can maintain the epithelial state through being in contact with its neighboring epithelial cancer cells. There is assumed to be no cell growth or death for macrophages and there is a maximum &#x0201c;carrying capacity&#x0201d; of cells in the system. The figure that illustrate this model is in Figure <xref ref-type="fig" rid="F1">1A</xref>. The equations to describe this system is as follows:</p><disp-formula id="E2"><mml:math id="M21"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>E</mml:mi></mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E3"><label>(1)</label><mml:math id="M22"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>M</mml:mi></mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E4"><mml:math id="M23"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><p>The description and the value of each parameter are given in Table <xref rid="T3" ref-type="table">3</xref>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Parameters used in our models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Parameters</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Values</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Normalization factor</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003bb;<sub>E</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B33" ref-type="bibr">33</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003bb;<sub>M</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B33" ref-type="bibr">33</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b1;</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B34" ref-type="bibr">34</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">K<sub>1</sub></td><td valign="top" align="left" rowspan="1" colspan="1">0.1 N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated (varied)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b7;<sub>me</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/120 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B38" ref-type="bibr">38</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b7;<sub>em</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B38" ref-type="bibr">38</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="M24"><mml:msubsup><mml:mrow><mml:mtext>K</mml:mtext></mml:mrow><mml:mrow><mml:mtext>M</mml:mtext></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td valign="top" align="left" rowspan="1" colspan="1">0.1 N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="M25"><mml:msubsup><mml:mrow><mml:mtext>K</mml:mtext></mml:mrow><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td valign="top" align="left" rowspan="1" colspan="1">0.1 N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">k</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b2;</td><td valign="top" align="left" rowspan="1" colspan="1">0 or 1/36 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B35" ref-type="bibr">35</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">K<sub>2</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1 N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1 or 2</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated (varied)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>m</italic></td><td valign="top" align="left" rowspan="1" colspan="1">1 or 2</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated (varied)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b2;<sub>c</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/1200 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b7;<sub>1</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/24 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B35" ref-type="bibr">35</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">K<sub>E</sub></td><td valign="top" align="left" rowspan="1" colspan="1">0.1 N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b7;<sub>2</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/24 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Symmetric assumption</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">K<sub>M</sub></td><td valign="top" align="left" rowspan="1" colspan="1">0.1 N<sub>max</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">K<sub>C</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="M26"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated (varied)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><inline-formula><mml:math id="M27"><mml:msubsup><mml:mrow><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Symmetric assumption (varied)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b7;<sub>12</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from (<xref rid="B35" ref-type="bibr">35</xref>) (varied)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b7;<sub>21</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1/72 h<sup>&#x02212;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Symmetric assumption (varied)</td></tr></tbody></table></table-wrap><p>In Model II, interconversions between M<sub>1</sub> and M<sub>2</sub> macrophages are included. Furthermore, the interconversions can be enhanced by corresponding cancer cells. The figure that illustrate this model is in Figure <xref ref-type="fig" rid="F2">2A</xref>. The equation to describe this system is as follows:</p><disp-formula id="E5"><mml:math id="M28"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>E</mml:mi></mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E6"><label>(2)</label><mml:math id="M29"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>M</mml:mi></mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E7"><mml:math id="M30"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E8"><mml:math id="M31"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E9"><mml:math id="M32"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math></disp-formula><p>In the third model, additional interactions were introduced as illustrated in Figure <xref ref-type="fig" rid="F3">3A</xref>. M<sub>1</sub>-like macrophages can induce apoptosis of epithelial cancer cells and factors released by apoptotic cancer cells can convert M<sub>1</sub>-like macrophages into M<sub>2</sub>-like macrophages. In order to restore the symmetry of the system, we further consider the therapeutic interaction: M<sub>2</sub>-like macrophages can be re-polarized back to M<sub>1</sub>-like macrophage by Type 1 T helper cells or IL-12. The equation to describe this system is as follows:</p><disp-formula id="E10"><mml:math id="M33"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>E</mml:mi></mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E11"><label>(3)</label><mml:math id="M34"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mo>&#x003bb;</mml:mo><mml:mi>M</mml:mi></mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>k</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>k</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><disp-formula id="E12"><mml:math id="M35"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mi>E</mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mi>C</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mi>C</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mi>C</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfrac><mml:mi>E</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>E</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b7;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><p>The description and the corresponding values of additional parameters are given in Table <xref rid="T3" ref-type="table">3</xref>.</p></sec><sec><title>Correlation Analysis</title><p>For a fixed dataset, linear regression was performed for each gene of interest against the predicted EMT score (<xref rid="B47" ref-type="bibr">47</xref>). In each case samples were discretized into EMT-high or EMT-low based on median EMT score for hypothesis testing. The linear correlation coefficient was recorded in each case. We performed statistical analysis under the null hypothesis of zero correlation between gene expression fold-change and EMT score and recorded the corresponding <italic>p</italic>-values at significance level &#x003b1; = 0.05 using unpaired <italic>t</italic>-test. All datasets (colon adenocarcinoma, <italic>n</italic> = 286; lung adenocarcinoma, <italic>n</italic> = 525; prostate adenocarcinoma, <italic>n</italic> = 497; breast invasive carcinoma, <italic>n</italic> = 1,097) were obtained from the R2: Genomics Analysis and Visualization Platform (<ext-link ext-link-type="uri" xlink:href="http://r2.amc.nl">http://r2.amc.nl</ext-link>).</p></sec></sec><sec id="s5"><title>Author Contributions</title><p>XL, MKJ, KJP, and HL designed research. XL, MKJ, and JTG performed research. MKJ and JTG analyzed data. XL, MKJ, KJP, and HL wrote the paper.</p><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was sponsored by the National Science Foundation NSF grant PHY-1427654 (Center for Theoretical Biological Physics). XL was supported by Stand Up to Cancer and The V Foundation. MKJ was also supported by a training fellowship from Gulf Coast Consortium as computational cancer biology training grant (CPRIT RP1705593). JTG was supported by National Cancer Institute of NIH (F30CA213878). KJP is supported by National Cancer Institute NCI grant CA093900. HL is also a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research of the State of Texas at Rice University.</p></fn></fn-group><sec sec-type="supplementary-material" id="s6"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2019.00010/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2019.00010/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group>. <article-title>Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers</article-title>. <source>J Clin Oncol</source>. (<year>2013</year>) <volume>31</volume>:<fpage>2205</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2012.46.3653</pub-id><?supplied-pmid 23669226?><pub-id pub-id-type="pmid">23669226</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocci</surname><given-names>F</given-names></name><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Tripathi</surname><given-names>SC</given-names></name><name><surname>Aguilar</surname><given-names>M</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signaling</article-title>. <source>J R Soc Interface</source> (<year>2017</year>) <volume>14</volume>:<fpage>20170512</fpage>
<pub-id pub-id-type="doi">10.1098/rsif.2017.0512</pub-id><pub-id pub-id-type="pmid">29187638</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>DH</given-names></name><name><surname>Ungewiss</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>P</given-names></name><name><surname>Byers</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Canales</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis</article-title>. <source>Oncogene</source> (<year>2016</year>) <volume>36</volume>:<fpage>1925</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2016.358</pub-id><?supplied-pmid 27694892?><pub-id pub-id-type="pmid">27694892</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name></person-group>. <article-title>The intercellular metabolic interplay between tumor and immune cells</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<fpage>358</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00358</pub-id><?supplied-pmid 25120544?><pub-id pub-id-type="pmid">25120544</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Pozo Martin</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Ombrato</surname><given-names>L</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Chakravarty</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization</article-title>. <source>Cell Rep.</source> (<year>2015</year>) <volume>13</volume>:<fpage>2456</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.11.025</pub-id><?supplied-pmid 26670048?><pub-id pub-id-type="pmid">26670048</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarsheth</surname><given-names>N</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group>. <article-title>Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</article-title>. <source>Nat Rev Immunol</source>. (<year>2017</year>) <volume>17</volume>:<fpage>559</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.49</pub-id><?supplied-pmid 28555670?><pub-id pub-id-type="pmid">28555670</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>JM</given-names></name><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group>. <article-title>Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy</article-title>. <source>Ann Oncol.</source> (<year>2016</year>) <volume>27</volume>:<fpage>1482</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdw168</pub-id><?supplied-pmid 27069014?><pub-id pub-id-type="pmid">27069014</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Bottazzi</surname><given-names>B</given-names></name><name><surname>Colotta</surname><given-names>F</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Ruco</surname><given-names>L</given-names></name></person-group>. <article-title>The origin and function of tumor-associated macrophages</article-title>. <source>Immunol Today</source> (<year>1992</year>) <volume>13</volume>:<fpage>265</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/0167-5699(92)90008-U</pub-id><?supplied-pmid 1388654?><pub-id pub-id-type="pmid">1388654</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noy</surname><given-names>R</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group>. <article-title>Tumor-associated macrophages: from mechanisms to therapy</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>:<fpage>49</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.010</pub-id><?supplied-pmid 25035953?><pub-id pub-id-type="pmid">25035953</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Schioppa</surname><given-names>T</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name></person-group>. <article-title>Role of tumor-associated macrophages in tumor progression and invasion</article-title>. <source>Cancer Metastasis Rev</source>. (<year>2006</year>) <volume>25</volume>:<fpage>315</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-006-9001-7</pub-id><?supplied-pmid 16967326?><pub-id pub-id-type="pmid">16967326</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Solinas</surname><given-names>G</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group>. <article-title>The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages</article-title>. <source>Crit Rev Oncol Hematol</source>. (<year>2008</year>) <volume>66</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2007.07.004</pub-id><?supplied-pmid 17913510?><pub-id pub-id-type="pmid">17913510</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solinas</surname><given-names>G</given-names></name><name><surname>Germano</surname><given-names>G</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name></person-group>. <article-title>Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation</article-title>. <source>J Leukoc Biol</source>. (<year>2009</year>) <volume>86</volume>:<fpage>1065</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0609385</pub-id><?supplied-pmid 19741157?><pub-id pub-id-type="pmid">19741157</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group>. <article-title>Macrophage plasticity and polarization: <italic>in vivo</italic> veritas</article-title>. <source>J Clin Invest</source>. (<year>2012</year>) <volume>122</volume>:<fpage>787</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1172/JCI59643</pub-id><?supplied-pmid 22378047?><pub-id pub-id-type="pmid">22378047</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name></person-group>. <article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title>. <source>Trends Immunol</source>. (<year>2002</year>) <volume>23</volume>:<fpage>549</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S1471-4906(02)02302-5</pub-id><?supplied-pmid 12401408?><pub-id pub-id-type="pmid">12401408</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edin</surname><given-names>S</given-names></name><name><surname>Wikberg</surname><given-names>ML</given-names></name><name><surname>Dahlin</surname><given-names>AM</given-names></name><name><surname>Ruteg&#x000e5;rd</surname><given-names>J</given-names></name><name><surname>&#x000d6;berg</surname><given-names>&#x000c5;</given-names></name><name><surname>Oldenborg</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>The Distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer</article-title>. <source>PLoS ONE</source> (<year>2012</year>) <volume>7</volume>:<fpage>e47045</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0047045</pub-id><?supplied-pmid 23077543?><pub-id pub-id-type="pmid">23077543</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohri</surname><given-names>CM</given-names></name><name><surname>Shikotra</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>RH</given-names></name><name><surname>Waller</surname><given-names>DA</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group>. <article-title>Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival</article-title>. <source>Eur Respir J</source>. (<year>2009</year>) <volume>33</volume>:<fpage>118</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00065708</pub-id><?supplied-pmid 19118225?><pub-id pub-id-type="pmid">19118225</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Che</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>N</given-names></name><name><surname>Dai</surname><given-names>F</given-names></name><name><surname>You</surname><given-names>Z</given-names></name></person-group>. <article-title>The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time</article-title>. <source>BMC Cancer</source> (<year>2010</year>) <volume>10</volume>:<fpage>112</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-10-112</pub-id><?supplied-pmid 20338029?><pub-id pub-id-type="pmid">20338029</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name></person-group>. <article-title>Effector T cell plasticity: flexibility in the face of changing circumstances</article-title>. <source>Nat Immunol</source>. (<year>2010</year>) <volume>11</volume>:<fpage>674</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1899</pub-id><?supplied-pmid 20644573?><pub-id pub-id-type="pmid">20644573</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>M</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Abas</surname><given-names>M</given-names></name><name><surname>Chaffee</surname><given-names>S</given-names></name><name><surname>Sen</surname><given-names>CK</given-names></name><etal/></person-group>. <article-title>Monocyte and macrophage plasticity in tissue repair and regeneration</article-title>. <source>Am J Pathol</source>. (<year>2015</year>) <volume>185</volume>:<fpage>2596</fpage>&#x02013;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.06.001</pub-id><?supplied-pmid 26118749?><pub-id pub-id-type="pmid">26118749</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghaddam</surname><given-names>AS</given-names></name><name><surname>Mohammadian</surname><given-names>S</given-names></name><name><surname>Vazini</surname><given-names>H</given-names></name><name><surname>Taghadosi</surname><given-names>M</given-names></name><name><surname>Esmaeili</surname><given-names>S-A</given-names></name><name><surname>Mardani</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Macrophage plasticity, polarization and function in health and disease</article-title>. <source>J Cell Physiol</source>. (<year>2018</year>) <volume>233</volume>:<fpage>6425</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.26429</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guiducci</surname><given-names>C</given-names></name><name><surname>Vicari</surname><given-names>AP</given-names></name><name><surname>Sangaletti</surname><given-names>S</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Colombo</surname><given-names>MP</given-names></name></person-group>. <article-title>Redirecting <italic>in vivo</italic> elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection</article-title>. <source>Cancer Res</source>. (<year>2005</year>) <volume>65</volume>:<fpage>3437</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4262</pub-id><?supplied-pmid 15833879?><pub-id pub-id-type="pmid">15833879</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolny</surname><given-names>C</given-names></name><name><surname>Mazzone</surname><given-names>M</given-names></name><name><surname>Tugues</surname><given-names>S</given-names></name><name><surname>Laoui</surname><given-names>D</given-names></name><name><surname>Johansson</surname><given-names>I</given-names></name><name><surname>Coulon</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF</article-title>. <source>Cancer Cell</source> (<year>2011</year>) <volume>19</volume>:<fpage>31</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.009</pub-id><?supplied-pmid 21215706?><pub-id pub-id-type="pmid">21215706</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype</article-title>. <source>J Immunol</source>. (<year>2015</year>) <volume>194</volume>:<fpage>4997</fpage>&#x02013;<lpage>5006</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1402603</pub-id><?supplied-pmid 25876763?><pub-id pub-id-type="pmid">25876763</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geeraerts</surname><given-names>X</given-names></name><name><surname>Bolli</surname><given-names>E</given-names></name><name><surname>Fendt</surname><given-names>SM</given-names></name><name><surname>Van Ginderachter</surname><given-names>JA</given-names></name></person-group>. <article-title>Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>289</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00289</pub-id><?supplied-pmid 28360914?><pub-id pub-id-type="pmid">28360914</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genard</surname><given-names>G</given-names></name><name><surname>Lucas</surname><given-names>S</given-names></name><name><surname>Michiels</surname><given-names>C</given-names></name></person-group>. <article-title>Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>828</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00828</pub-id><?supplied-pmid 28769933?><pub-id pub-id-type="pmid">28769933</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Jackson</surname><given-names>RA</given-names></name><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group>. <article-title>EMT: 2016</article-title>. <source>Cell</source> (<year>2016</year>) <volume>166</volume>:<fpage>21</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id><?supplied-pmid 27368099?><pub-id pub-id-type="pmid">27368099</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Ware</surname><given-names>KE</given-names></name><name><surname>Gilja</surname><given-names>S</given-names></name><name><surname>Somarelli</surname><given-names>JA</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group>
<article-title>EMT and MET: necessary or permissive for metastasis?</article-title>
<source>Mol Oncol</source>. (<year>2017</year>) <volume>11</volume>:<fpage>755</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.12083</pub-id><pub-id pub-id-type="pmid">28548345</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>AM</given-names></name><name><surname>Mitschke</surname><given-names>J</given-names></name><name><surname>Losada</surname><given-names>ML</given-names></name><name><surname>Schmalhofer</surname><given-names>O</given-names></name><name><surname>Boerries</surname><given-names>M</given-names></name><name><surname>Busch</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer</article-title>. <source>Nat Cell Biol</source>. (<year>2017</year>) <volume>19</volume>:<fpage>518</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/ncb3513</pub-id><?supplied-pmid 28414315?><pub-id pub-id-type="pmid">28414315</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siebzehnrubl</surname><given-names>FA</given-names></name><name><surname>Silver</surname><given-names>DJ</given-names></name><name><surname>Tugertimur</surname><given-names>B</given-names></name><name><surname>Deleyrolle</surname><given-names>LP</given-names></name><name><surname>Siebzehnrubl</surname><given-names>D</given-names></name><name><surname>Sarkisian</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance</article-title>. <source>EMBO Mol Med.</source> (<year>2013</year>) <volume>5</volume>:<fpage>1196</fpage>&#x02013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1002/emmm.201302827</pub-id><?supplied-pmid 23818228?><pub-id pub-id-type="pmid">23818228</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Boareto</surname><given-names>M</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Ben-Jacob</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Coupling the modules of EMT and stemness: A tunable &#x0201c;stemness window&#x0201d; model</article-title>. <source>Oncotarget</source> (<year>2015</year>) <volume>6</volume>:<fpage>25161</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.4629</pub-id><pub-id pub-id-type="pmid">26317796</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RYJ</given-names></name><name><surname>Wong</surname><given-names>MK</given-names></name><name><surname>Tan</surname><given-names>TZ</given-names></name><name><surname>Kuay</surname><given-names>KT</given-names></name><name><surname>Ng</surname><given-names>AHC</given-names></name><name><surname>Chung</surname><given-names>VY</given-names></name><etal/></person-group>. <article-title>An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)</article-title>. <source>Cell Death Dis</source>. (<year>2013</year>) <volume>4</volume>:<fpage>e915</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.442</pub-id><?supplied-pmid 24201814?><pub-id pub-id-type="pmid">24201814</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>SC</given-names></name><name><surname>Peters</surname><given-names>HL</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Katayama</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Momin</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2016</year>) <volume>113</volume>:<fpage>E1555</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1521812113</pub-id><?supplied-pmid 26929325?><pub-id pub-id-type="pmid">26929325</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollm&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Roudnicky</surname><given-names>F</given-names></name><name><surname>Karaman</surname><given-names>S</given-names></name><name><surname>Detmar</surname><given-names>M</given-names></name></person-group>. <article-title>Characterization of macrophage&#x02013;cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>9188</fpage>. <pub-id pub-id-type="doi">10.1038/srep09188</pub-id><?supplied-pmid 25776849?><pub-id pub-id-type="pmid">25776849</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>A</given-names></name><name><surname>Hsiao</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Ho</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><etal/></person-group>. <article-title>Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>14273</fpage>. <pub-id pub-id-type="doi">10.1038/srep14273</pub-id><?supplied-pmid 26399191?><pub-id pub-id-type="pmid">26399191</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weigert</surname><given-names>A</given-names></name><name><surname>Tzieply</surname><given-names>N</given-names></name><name><surname>von Knethen</surname><given-names>A</given-names></name><name><surname>Johann</surname><given-names>AM</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Geisslinger</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate</article-title>. <source>Mol Biol Cell</source> (<year>2007</year>) <volume>18</volume>:<fpage>3810</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E06-12-1096</pub-id><?supplied-pmid 17652460?><pub-id pub-id-type="pmid">17652460</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>S</given-names></name><name><surname>Brion</surname><given-names>R</given-names></name><name><surname>Lintunen</surname><given-names>M</given-names></name><name><surname>Kronqvist</surname><given-names>P</given-names></name><name><surname>Sandholm</surname><given-names>J</given-names></name><name><surname>M&#x000f6;nkk&#x000f6;nen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Human breast cancer cells educate macrophages toward the M2 activation status</article-title>. <source>Breast Cancer Res</source>. (<year>2015</year>) <volume>17</volume>:<fpage>101</fpage>. <pub-id pub-id-type="doi">10.1186/s13058-015-0621-0</pub-id><?supplied-pmid 26243145?><pub-id pub-id-type="pmid">26243145</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A Positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis</article-title>. <source>Cancer Cell</source> (<year>2014</year>) <volume>25</volume>:<fpage>605</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2014.03.021</pub-id><?supplied-pmid 24823638?><pub-id pub-id-type="pmid">24823638</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Clark</surname><given-names>AM</given-names></name><name><surname>Wells</surname><given-names>A</given-names></name></person-group>. <article-title>Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells</article-title>. <source>BMC Cancer</source> (<year>2016</year>) <volume>16</volume>:<fpage>419</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-016-2411-1</pub-id><?supplied-pmid 27387344?><pub-id pub-id-type="pmid">27387344</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mobius</surname><given-names>W</given-names></name><name><surname>Laan</surname><given-names>L</given-names></name></person-group>. <article-title>Physical and mathematical modeling in experimental papers</article-title>. <source>Cell</source> (<year>2015</year>) <volume>163</volume>:<fpage>1577</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.12.006</pub-id><?supplied-pmid 26687351?><pub-id pub-id-type="pmid">26687351</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>PA</given-names></name><name><surname>Bracken</surname><given-names>CP</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Bert</surname><given-names>AG</given-names></name><name><surname>Wright</surname><given-names>JA</given-names></name><name><surname>Roslan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition</article-title>. <source>Mol Biol Cell</source> (<year>2011</year>) <volume>22</volume>:<fpage>1686</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E11-02-0103</pub-id><?supplied-pmid 21411626?><pub-id pub-id-type="pmid">21411626</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheel</surname><given-names>C</given-names></name><name><surname>Eaton</surname><given-names>EN</given-names></name><name><surname>Li</surname><given-names>SHJ</given-names></name><name><surname>Chaffer</surname><given-names>CL</given-names></name><name><surname>Reinhardt</surname><given-names>F</given-names></name><name><surname>Kah</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast</article-title>. <source>Cell</source> (<year>2011</year>) <volume>145</volume>:<fpage>926</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.04.029</pub-id><?supplied-pmid 21663795?><pub-id pub-id-type="pmid">21663795</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmalhofer</surname><given-names>O</given-names></name><name><surname>Brabletz</surname><given-names>S</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name></person-group>. <article-title>E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer</article-title>. <source>Cancer Metastasis Rev</source>. (<year>2009</year>) <volume>28</volume>:<fpage>151</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-008-9179-y</pub-id><?supplied-pmid 19153669?><pub-id pub-id-type="pmid">19153669</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Harrison</surname><given-names>W</given-names></name><name><surname>Boareto</surname><given-names>M</given-names></name><name><surname>Ben-Jacob</surname><given-names>E</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group>. <article-title>Operating principles of tristable circuits regulating cellular differentiation</article-title>. <source>Phys Biol</source>. (<year>2017</year>) <volume>14</volume>:<fpage>035007</fpage>. <pub-id pub-id-type="doi">10.1088/1478-3975/aa6f90</pub-id><?supplied-pmid 28443829?><pub-id pub-id-type="pmid">28443829</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusinkveld</surname><given-names>M</given-names></name><name><surname>de Vos van Steenwijk</surname><given-names>PJ</given-names></name><name><surname>Goedemans</surname><given-names>R</given-names></name><name><surname>Ramwadhdoebe</surname><given-names>TH</given-names></name><name><surname>Gorter</surname><given-names>A</given-names></name><name><surname>Welters</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells</article-title>. <source>J Immunol</source>. (<year>2011</year>) <volume>187</volume>:<fpage>1157</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1100889</pub-id><?supplied-pmid 21709158?><pub-id pub-id-type="pmid">21709158</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Y-X</given-names></name><name><surname>Qiao</surname><given-names>S-L</given-names></name><name><surname>An</surname><given-names>H-W</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>Z-Y</given-names></name><etal/></person-group>. <article-title>Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment</article-title>. <source>Biomaterials</source> (<year>2017</year>) <volume>112</volume>:<fpage>153</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/J.BIOMATERIALS.2016.09.034</pub-id><?supplied-pmid 27768970?><pub-id pub-id-type="pmid">27768970</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>JJ</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Coffey</surname><given-names>DS</given-names></name></person-group>. <article-title>Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>9</volume>:<fpage>11429</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.22939</pub-id><?supplied-pmid 29545909?><pub-id pub-id-type="pmid">29545909</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JT</given-names></name><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Somarelli</surname><given-names>JA</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group>. <article-title>Survival outcomes in cancer patients predicted by a partial EMT gene expression scoring metric</article-title>. <source>Cancer Res</source>. (<year>2017</year>) <volume>77</volume>:<fpage>6415</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3521</pub-id><?supplied-pmid 28947416?><pub-id pub-id-type="pmid">28947416</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Amici</surname><given-names>SA</given-names></name><name><surname>Webb</surname><given-names>LM</given-names></name><name><surname>Ruiz-Rosado</surname><given-names>JDD</given-names></name><name><surname>Popovich</surname><given-names>PG</given-names></name><name><surname>Partida-Sanchez</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Novel markers to delineate murine M1 and M2 macrophages</article-title>. <source>PLoS ONE</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0145342</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0145342</pub-id><?supplied-pmid 26699615?><pub-id pub-id-type="pmid">26699615</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group>. <article-title>The tumor microenvironment and its role in promoting tumor growth</article-title>. <source>Oncogene</source> (<year>2008</year>) <volume>27</volume>:<fpage>5904</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2008.271</pub-id><?supplied-pmid 18836471?><pub-id pub-id-type="pmid">18836471</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Schreiber</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group>. <article-title>Innate and adaptive immune cells in the tumor microenvironment</article-title>. <source>Nat Immunol</source>. (<year>2013</year>) <volume>14</volume>:<fpage>1014</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2703</pub-id><?supplied-pmid 24048123?><pub-id pub-id-type="pmid">24048123</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augsten</surname><given-names>M</given-names></name></person-group>. <article-title>Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment</article-title>. <source>Front Oncol</source>. (<year>2014</year>) <volume>4</volume>:<fpage>62</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2014.00062</pub-id><?supplied-pmid 24734219?><pub-id pub-id-type="pmid">24734219</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsov</surname><given-names>VA</given-names></name><name><surname>Knott</surname><given-names>GD</given-names></name></person-group>
<article-title>Modeling tumor regrowth and immunotherapy</article-title>. <source>Math Comput Model</source> (<year>2001</year>) <volume>33</volume>:<fpage>1275</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/S0895-7177(00)00314-9</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kn&#x000fa;tsd&#x000f3;ttir</surname><given-names>H</given-names></name><name><surname>P&#x000e1;lsson</surname><given-names>E</given-names></name><name><surname>Edelstein-Keshet</surname><given-names>L</given-names></name></person-group>. <article-title>Mathematical model of macrophage-facilitated breast cancer cells invasion</article-title>. <source>J Theor Biol</source>. (<year>2014</year>) <volume>357</volume>:<fpage>184</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2014.04.031</pub-id><?supplied-pmid 24810842?><pub-id pub-id-type="pmid">24810842</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutsdottir</surname><given-names>H</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name><name><surname>Palsson</surname><given-names>E</given-names></name></person-group>. <article-title>3-D individual cell based computational modeling of tumor cell&#x02013;macrophage paracrine signaling mediated by EGF and CSF-1 gradients</article-title>. <source>Integr Biol.</source> (<year>2016</year>) <volume>8</volume>:<fpage>104</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1039/C5IB00201J</pub-id><?supplied-pmid 26686751?><pub-id pub-id-type="pmid">26686751</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serre</surname><given-names>R</given-names></name><name><surname>Benzekry</surname><given-names>S</given-names></name><name><surname>Padovani</surname><given-names>L</given-names></name><name><surname>Meille</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>N</given-names></name><name><surname>Ciccolini</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy</article-title>. <source>Cancer Res.</source> (<year>2016</year>) <volume>76</volume>:<fpage>4931</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3567</pub-id><?supplied-pmid 27302167?><pub-id pub-id-type="pmid">27302167</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><name><surname>MacLean</surname><given-names>AL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group>. <article-title>Multiscale modeling of inflammation-induced tumorigenesis reveals competing oncogenic and oncoprotective roles for inflammation</article-title>. <source>Cancer Res</source>. (<year>2017</year>) <volume>77</volume>:<fpage>6429</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1662</pub-id><?supplied-pmid 28951462?><pub-id pub-id-type="pmid">28951462</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahlbacher</surname><given-names>G</given-names></name><name><surname>Curtis</surname><given-names>LT</given-names></name><name><surname>Lowengrub</surname><given-names>J</given-names></name><name><surname>Frieboes</surname><given-names>HB</given-names></name></person-group>. <article-title>Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment</article-title>. <source>J Immunother Cancer</source> (<year>2018</year>) <volume>6</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/s40425-017-0313-7</pub-id><?supplied-pmid 29382395?><pub-id pub-id-type="pmid">29382395</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michor</surname><given-names>F</given-names></name><name><surname>Beal</surname><given-names>K</given-names></name></person-group>. <article-title>Improving cancer treatment via mathematical modeling: surmounting the challenges is worth the effort</article-title>. <source>Cell</source> (<year>2015</year>) <volume>163</volume>:<fpage>1059</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.11.002</pub-id><?supplied-pmid 26590416?><pub-id pub-id-type="pmid">26590416</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>AR</given-names></name><name><surname>Nam</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>J-Y</given-names></name><name><surname>Seo</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6+ cancer cell and macrophage polarization</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>5108</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-07470-w</pub-id><?supplied-pmid 30504836?><pub-id pub-id-type="pmid">30504836</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storer</surname><given-names>M</given-names></name><name><surname>Mas</surname><given-names>A</given-names></name><name><surname>Robert-Moreno</surname><given-names>A</given-names></name><name><surname>Pecoraro</surname><given-names>M</given-names></name><name><surname>Ortells</surname><given-names>MC</given-names></name><name><surname>Di Giacomo</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Senescence is a developmental mechanism that contributes to embryonic growth and patterning</article-title>. <source>Cell</source> (<year>2013</year>) <volume>155</volume>:<fpage>1119</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.10.041</pub-id><?supplied-pmid 24238961?><pub-id pub-id-type="pmid">24238961</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Ward</surname><given-names>C</given-names></name><name><surname>Eapen</surname><given-names>MS</given-names></name><name><surname>Myers</surname><given-names>S</given-names></name><name><surname>Hallgren</surname><given-names>O</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Epithelial&#x02013;mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease</article-title>. <source>Dev Dyn</source> (<year>2018</year>) <volume>247</volume>:<fpage>346</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1002/dvdy.24541</pub-id><?supplied-pmid 28646553?><pub-id pub-id-type="pmid">28646553</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aras</surname><given-names>S</given-names></name><name><surname>Raza Zaidi</surname><given-names>M</given-names></name></person-group>. <article-title>TAMeless traitors: macrophages in cancer progression and metastasis</article-title>. <source>Br J Cancer</source> (<year>2017</year>) <volume>117</volume>:<fpage>1583</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2017.356</pub-id><?supplied-pmid 29065107?><pub-id pub-id-type="pmid">29065107</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amend</surname><given-names>SR</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name></person-group>. <article-title>Ecological paradigms to understand the dynamics of metastasis</article-title>. <source>Cancer Lett</source>. (<year>2016</year>) <volume>380</volume>:<fpage>237</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2015.10.005</pub-id><?supplied-pmid 26458994?><pub-id pub-id-type="pmid">26458994</pub-id></mixed-citation></ref></ref-list></back></article>